Abstract
AbstractThis paper explores some of the concerns associated with the new group of oral anti‐cancer agents from the standpoint of availability, direct costs to the patient, and pricing strategies. We sought to evaluate the availability in the United States and the United Kingdom based on approval times. We then consulted select insurance companies' websites for 2011, the online Medicare Part D donut‐hole calculator, and the Cancer U.K. website for cost information. Nine oral targeted agents are approved both in the United States and United Kingdom. The date of approval was earlier in the United States compared to the United Kingdom for every medication, and Medicare patients have the highest out‐of‐pocket payments. Oral oncology products are available earlier in United States than in United Kingdom. Potential high out‐of‐pocket liability for Medicare patients is a greater obstacle to access than is the case for U.S. commercial insurance or National Health System (NHS) patients in the United Kingdom.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
